Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference.

A live webcast of the presentation will be available on the link provided below for approximately 30 days.

About Nuvectis Pharma

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. The Company's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in IND-enabling pre-clinical testing.

For more information, please visit www.nuvectis.com.

Nuvectis Pharma Contact:

Ron Bentsur

Chairman, Chief Executive Officer and President

This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Relations Contact:

Christopher M. Calabrese

LifeSci Advisors

Tel: 917-680-5608

This email address is being protected from spambots. You need JavaScript enabled to view it.